MEDBOLIDE - KD2: SUMMARY OF THE FIRST 6 MONTHS OF 2026: LOOKING BACK ON OUR JOURNEY – BREAKTHROUGHS FOR THE NEXT PHASE

On July 24, 2026, Team KD2 successfully organized the “First Half of 2026 Review” event, attended by CEO, HR, the Head of BUM2, and the entire BU2 team nationwide.

This was an important event aimed at evaluating performance results for the first six months of the year, recognizing the team’s efforts, and setting strategic directions for the final push of 2026.

Highlights of the First Half of the Year

Amid a rapidly changing pharmaceutical market, the BU2 team has continuously innovated, adapted, and worked hard to achieve its assigned goals. With a proactive and responsible approach and a commitment to working closely with customers, BU2 continues to expand its market reach, enhance the quality of customer service, and strengthen its partnerships with hospitals, clinics, and partners nationwide.

The results achieved in the first six months of the year are the product of the unity, determination, and professional work ethic of the entire team, along with the close guidance of the Company’s Leadership Team.

Guidelines for the Last 6 Months of the Year

As it enters a phase of accelerated growth, BUM2 has outlined its key strategic priorities aimed at improving operational efficiency and laying the foundation for sustainable development.

To conclude the program, the BU2 team demonstrated a strong determination to enter the final six months of the year with a spirit of Unity – Discipline – Professionalism – Efficiency, ready to make a breakthrough to achieve the set goals, contributing to the continued growth of Medbolide Pharmaceutical JSC, affirming its position in the market, and continuing to fulfill its mission of delivering quality products for the sake of public health.